ArticleJournal of natural medicines2024
Byakangelicin alleviates sepsis-associated acute kidney injury by inhibiting inflammation and apoptosis.
Article in Journal of natural medicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Serum HDAC3 as an early biomarker for prediction and staging of sepsis-associated AKI: prospective cohort study.BMC infectious diseases · 2026Article
- Current Status and Future Prospects of Research on Sepsis-Related Acute Kidney Injury.International journal of molecular sciences · 2026Review
- Structure-activity relationships and molecular mechanisms of natural products in sepsis-associated organ dysfunction: a narrative review.Frontiers in pharmacology · 2026Review
- Phytochemical Profiling, Acute Toxicity, and Hepatoprotective Effects ofFood science & nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation and apoptosis are common in many pathological conditions. Studies have shown that many natural compounds can regulate the signal pathways related to inflammation and apoptosis and can prevent sepsis-associated acute kidney injury (SA-AKI). Several studies have reported the potential anti-inflammatory effect of byakangelicin (BK), a component from the roots of Angelica gigas. However, the role of BK in SA-AKI remains unknown. Here, we report that BK is a potential therapeutic drug for SA-AKI. Experimental results show that BK has high anti-inflammatory activity, inhibits the activation of the NF-κB signaling pathway, and then reduces the production of IL-6, TNF-a, and IFN-γ. In addition, we study the effect of BK on renal cell apoptosis and find that BK significantly reduces the expression of apoptosis-related genes. Further research suggests that BK may exert the above pharmacological effects through 26S protease regulatory subunit 8 (PSMC5). These findings indicate that BK, as an inhibitor of inflammation and apoptosis, can be used to treat SA-AKI.
Indexed as
Identifiers
38809334What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.